deltatrials
Terminated PHASE2 NCT00104884

FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma

Phase II Trial of Depsipeptide (NSC 630176) in Advanced Malignant Melanoma

Sponsor: ECOG-ACRIN Cancer Research Group

Conditions Malignant Melanoma Melanoma
Interventions Depsipeptide
Updated 7 times since 2017 Last updated: Jun 13, 2023 Started: Oct 4, 2005 Primary completion: May 31, 2006 Completion: Mar 31, 2009

A PHASE2 clinical study on Malignant Melanoma and Melanoma, this trial is terminated or withdrawn. The trial is conducted by ECOG-ACRIN Cancer Research Group and has accumulated 7 data snapshots since 2005. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jul 2023 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jan 2021 — Jul 2023 [monthly]

    Terminated PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

Oct 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • ECOG-ACRIN Cancer Research Group
  • National Cancer Institute (NCI)
Data source: Eastern Cooperative Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.